Dabrafenib (GSK2118436)

目录号：S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格 价格 库存 购买数量  
RMB 1481.39 现货
RMB 733.64 现货
RMB 1056.75 现货
RMB 1394.46 现货
RMB 2235.84 现货
RMB 3261.37 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献19篇：

客户使用该产品的8个实验数据：

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blots for untreated, early, and late tumors.

    Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。
靶点
B-Raf (V600E) [3]
(Cell-free assay)		 B-Raf [3]
(Cell-free assay)		 C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-RafV600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-RafV600E的癌细胞中细胞停滞在G1期。
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MoT5T4lv[XOnIFHzd4F6 MUPJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER|M4KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1? M4LOclI1QTByNkez
SK-MEL-28 M{\5ZWtqdmG|ZTDBd5NigQ>? M1[4NFEhcA>? NIrmUGJKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODRizszN NWTnUmJQOjR7MEC2O|M>
HepG2 NYL4OoxvU2mwYYPlJGF{e2G7 NFiwUnZKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1? NFHLfmUzPDlyME[3Ny=>
COLO205 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KweWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= MlzrNlQ6ODB4N{O=
HepG2 M4[1SWZ2dmO2aX;uJGF{e2G7 NY\lUXFFPDVibXnu MYHEUXNQ MX\Jcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG|dYLl[EBi\nSncjC2NEBucW6|IHL5JI9lgXO|ZYmgZoxwfCC|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch|ryP MlywNlQ6ODB4N{O=
HFF M{nZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmryNVAh|ryP MWm3NkBp M13GOWROW09? NYLZcWVnUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIHj1cYFvKEiIRjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIFKtVoFnKHerdHigTWM2OCCxZjCzJO69VQ>? Mn\3NlM5PDRyM{i=
SK-MEL-28 NXPmNXhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNEDPxE1? NXjNe4ZVPzJiaB?= MXfEUXNQ M1fnOGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0> MXuyN|g1PDB|OB?=
A375P-F11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XaR|ExKM7:TR?= MnXVO|IhcA>? Ml3WSG1UVw>? M1r2VGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0> M3rjc|I{QDR2MEO4
MALME-3M M3PZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jUPVExKM7:TR?= NUTBOXY{PzJiaB?= Mki2SG1UVw>? MUPJR|UxRTFibl2= NXrPSIdROjN6NESwN|g>
UACC-62 M2XEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTFNVAh|ryP M2T4PVczKGh? NV;pOIdVTE2VTx?= MVLJR|UxRTFibl2= NXXzVZlIOjN6NESwN|g>
C32TG NXX3cXplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxNEDPxE1? M3\uZlczKGh? NWXCWGQyTE2VTx?= M4XYRWlEPTB;MTDuUS=> MoH1NlM5PDRyM{i=
SK-MEL-1 NGfSeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrxVo0yOCEQvF2= MWO3NkBp M{nkfmROW09? MVnJR|UxRTJibl2= NFf2VnQzOzh2NECzPC=>
M14 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj2b5cyOCEQvF2= M17h[VczKGh? NIPLS|hFVVOR MnrOTWM2OD1{IH7N NVzxVmd6OjN6NESwN|g>
SK-MEL-28 M2XjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG2NlkyOCEQvF2= MUe3NkBp Ml[5SG1UVw>? NFvjTWRKSzVyPUOgcm0> MUSyN|g1PDB|OB?=
A375 NFj5NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne1NVAh|ryP NITtd3U4OiCq MXvEUXNQ M372TmlEPTB;NDDuUS=> M1vpZ|I{QDR2MEO4
DU-4475 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3mV|QyOCEQvF2= MWG3NkBp MoHuSG1UVw>? NVXJdHNOUUN3ME21JI5O MkX5NlM5PDRyM{i=
UACC-257 M17YOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vCNVExKM7:TR?= NXPsb3dLPzJiaB?= NU\vTm9ETE2VTx?= NWGz[5JzUUN3ME22JI5O M{DHclI{QDR2MEO4
Colo 205 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNEDPxE1? NW\5WGx6PzJiaB?= NIHTOIdFVVOR MornTWM2OD15IH7N M3jrblI{QDR2MEO4
SK-MEL-3 NVXOdZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXHboZ6OTBizszN NVO5W4hHPzJiaB?= NWrTZlFNTE2VTx?= MlXDTWM2OD15IH7N NW\MbYxQOjN6NESwN|g>
SH-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyxNEDPxE1? MnuxO|IhcA>? M2fzUGROW09? MVfJR|UxRThibl2= MnTzNlM5PDRyM{i=
A101D NIezRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjNVAh|ryP MoTEO|IhcA>? MUjEUXNQ MnvHTWM2OD17IH7N NVu3bG84OjN6NESwN|g>
ES-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G2elExKM7:TR?= M{\Se|czKGh? Ml\iSG1UVw>? MXnJR|UxRTV|IH7N MVyyN|g1PDB|OB?=
HT-29 M3nWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrWPJMyOCEQvF2= NVHlXo1sPzJiaB?= NVXTcJYyTE2VTx?= NXXyWJh5UUN3ME22OkBvVQ>? NVj2W2Q6OjN6NESwN|g>
SW1417 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKxNEDPxE1? MU[3NkBp M1nXS2ROW09? M4T0ZWlEPTB;MUW4JI5O NYfBPG16OjN6NESwN|g>
SW872 NVz6UoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j5N|ExKM7:TR?= NF:yZYY4OiCq Mn[1SG1UVw>? MoHSTWM2OD1|N{egcm0> NI\UR5czOzh2NECzPC=>
RKO NFL6RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX3PXpTOTBizszN NVnQb|V3PzJiaB?= Mlr2SG1UVw>? MULJR|UxRTJwNUKyJO69VQ>? M2jLOFI{QDR2MEO4
A673 NWKyfWYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz2NVAh|ryP MW[3NkBp NGDjfnJFVVOR NXnydYV2UUN3ME2xNEDPxE1? M1;DUlI{QDR2MEO4
GCT NHrKUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HLTlExKM7:TR?= MV:3NkBp MkfESG1UVw>? MVrJR|UxRTFyIN88US=> MV[yN|g1PDB|OB?=
WM-115 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrENVAh|ryP NHnkWnM4OiCq M3;QdmROW09? MWPJR|UxRTVibl2= Mn\3NlM5PDRyM{i=
YUMAC MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHtPFdrOTBizszN Mm\6O|IhcA>? NVzKfYo3TE2VTx?= M1nO[2lEPTB;NTDuUS=> NH\6clEzOzh2NECzPC=>
OV-90 NGG3UVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOyU3VvOTBizszN MoT1O|IhcA>? M33pZ2ROW09? NYWz[Y03UUN3ME2yPUBvVQ>? NF34N3ozOzh2NECzPC=>
NCI-H508 NHjJdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn3UoNLOTBizszN NVGzbnVzPzJiaB?= NULWbHVZTE2VTx?= MYnJR|UxRTFyIN88US=> NXK0OG5LOjN6NESwN|g>
MDA-MB-231 M{TVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexNEDPxE1? MkTxO|IhcA>? Mn\VSG1UVw>? MorWTWM2OD1zMDFOwG0> NGHYNHYzOzh2NECzPC=>
SW756 M3vSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7lfY1VOTBizszN M4HGclczKGh? M1nlTGROW09? MW\JR|UxRTFyIN88US=> NIjPb5YzOzh2NECzPC=>
SW-837 NYTkXW9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWxNEDPxE1? NH\VS|A4OiCq MUHEUXNQ NXPCfnNHUUN3ME2xNEDPxE1? NYLifndvOjN6NESwN|g>
UMUC-3 NFewOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNEDPxE1? MV:3NkBp NV74fopFTE2VTx?= NWTRdohoUUN3ME2xNEDPxE1? NUDCWW13OjN6NESwN|g>
LS-174T NEPzc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj2NVAh|ryP MlflO|IhcA>? NVnFSIpCTE2VTx?= MWTJR|UxRTFyIN88US=> MmT6NlM5PDRyM{i=
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW1NVAh|ryP M3\FflczKGh? NHO2PHZFVVOR MUDJR|UxRTFyIN88US=> NHLycoozOzh2NECzPC=>
SHP-77 NFfnVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqxNEDPxE1? MlW4O|IhcA>? MVzEUXNQ NXjMOot3UUN3ME2xNEDPxE1? MUKyN|g1PDB|OB?=
SW480 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HLelExKM7:TR?= MU[3NkBp MUDEUXNQ NWfPfVdLUUN3ME2xNEDPxE1? M{L2VlI{QDR2MEO4
DLD-1 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxNEDPxE1? NFX1Upk4OiCq MWXEUXNQ M{\jU2lEPTB;MUCg{txO Mk\1NlM5PDRyM{i=
HCT-116 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\we2ZDOTBizszN NX7JNVNvPzJiaB?= MnL1SG1UVw>? NILYWWFKSzVyPUGwJO69VQ>? MoT2NlM5PDRyM{i=
NCI-H747 NEXLUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNEDPxE1? MknQO|IhcA>? M33qXWROW09? NV\Xc25FUUN3ME2xNEDPxE1? NVKxUYJ5OjN6NESwN|g>
T-84 NU[2[4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? MnHUO|IhcA>? M1\YPGROW09? MXPJR|UxRTFyIN88US=> M1nDWVI{QDR2MEO4
NCI-H460 M3jRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O2XlExKM7:TR?= NW\sVlBEPzJiaB?= MmXlSG1UVw>? M1LtTGlEPTB;MUCg{txO NVj3NG5{OjN6NESwN|g>
Calu-6 NV7sPWtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrVT2wyOCEQvF2= NHKyO|I4OiCq MYXEUXNQ M{\DXmlEPTB;MUCg{txO NFO0[2szOzh2NECzPC=>
HCC-2998 NF7i[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxNEDPxE1? M2XMRlczKGh? NVHaVZJUTE2VTx?= MlywTWM2OD1zMDFOwG0> Ml3RNlM5PDRyM{i=
LS1034 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC0Z3U2OTBizszN NFLzTFE4OiCq MlLPSG1UVw>? NFTuUVBKSzVyPUGwJO69VQ>? M2HmbFI{QDR2MEO4
CHP-212 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6xNEDPxE1? MmfDO|IhcA>? MXPEUXNQ MXXJR|UxRTFyIN88US=> MUeyN|g1PDB|OB?=
SK-N-AS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[xNEDPxE1? MnjrO|IhcA>? M4[wNGROW09? MUfJR|UxRTFyIN88US=> MUmyN|g1PDB|OB?=
BFTC-905 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfPZZgyOCEQvF2= NHPXdHc4OiCq M4XhZ2ROW09? Mnj4TWM2OD1zMDFOwG0> M1Hpc|I{QDR2MEO4
HuT78 M3;ESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DHVlExKM7:TR?= NUO0UFNsPzJiaB?= NWPMSIlCTE2VTx?= MkHRTWM2OD13MjDuUS=> NWDUfIR2OjN6NESwN|g>
RPMI-8226 M4LMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXWIE3OTBizszN NHvXcII4OiCq NID5PJVFVVOR NFHFUlBKSzVyPUK2N{BvVQ>? NInxVZEzOzh2NECzPC=>
BC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\5UVdoOTBizszN MVK3NkBp NF\YZppFVVOR NXnVWY9RUUN3ME2yO|chdk1? M1zNOVI{QDR2MEO4
ACHN M2nNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW5NVAh|ryP NUjNbG5GPzJiaB?= M4HCdmROW09? NHiw[nNKSzVyPUK5OEBvVQ>? MX[yN|g1PDB|OB?=
JRT3-T35 NXL0OFdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPEWZlNOTBizszN NXTTPINFPzJiaB?= NWi2TJR7TE2VTx?= NFfkfGlKSzVyPUK5OUBvVQ>? MmXONlM5PDRyM{i=
SK-MES-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j5c|ExKM7:TR?= NFnRe3c4OiCq MYXEUXNQ MUHJR|UxRTN{OTDuUS=> MYKyN|g1PDB|OB?=
CESS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[xNVExKM7:TR?= MUW3NkBp MmjsSG1UVw>? M3W3bWlEPTB;NEm3JI5O M2[4blI{QDR2MEO4
H4 NHW4fndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D2elExKM7:TR?= NVWw[FlSPzJiaB?= MYXEUXNQ MnXLTWM2OD14MUmgcm0> NWLHdmhVOjN6NESwN|g>
BC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELGNIwyOCEQvF2= NIH6OFg4OiCq NF\aW4JFVVOR MVLJR|UxRTdyNDDuUS=> M3\4dlI{QDR2MEO4
DB MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxNEDPxE1? MYC3NkBp MkGzSG1UVw>? MUXJR|UxRTh5MzDuUS=> M3vzeFI{QDR2MEO4
RPMI-6666 NEfWdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W1b|ExKM7:TR?= Mo\qO|IhcA>? MV;EUXNQ NXiweYY2UUN3ME25Nlghdk1? NVLVToVSOjN6NESwN|g>
MC/CAR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFPFc5OTBizszN MlHKO|IhcA>? NUK5PGtUTE2VTx?= MoTkTWM2OD1zLkCwNkDPxE1? MUSyN|g1PDB|OB?=
SNU-1 NVrMcWRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNEDPxE1? NELH[YQ4OiCq MlLMSG1UVw>? MofwTWM2OD1zLkWwNUDPxE1? NU\4PYdjOjN6NESwN|g>
CEM/C1 NVnBVXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjKcWwyOCEQvF2= NEjaUIw4OiCq MWTEUXNQ NFr6NnFKSzVyPUGuO|c{KM7:TR?= M3TLd|I{QDR2MEO4
GDM-1 M{Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNEDPxE1? Mn;HO|IhcA>? NHHPNXFFVVOR NUHFXmtNUUN3ME2xMlk6PyEQvF2= M2f0RlI{QDR2MEO4
HT-1080 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxNEDPxE1? MnWyO|IhcA>? MoTKSG1UVw>? Mkj2TWM2OD1{LkCwOEDPxE1? NVPPV4llOjN6NESwN|g>
HL-60 NFT0SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4NVAh|ryP NGruXZk4OiCq MlTLSG1UVw>? MWPJR|UxRTJwMUe4JO69VQ>? MWWyN|g1PDB|OB?=
C3A M3m3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjiXowyOCEQvF2= NYjkbFNWPzJiaB?= NUfLU2RtTE2VTx?= MV7JR|UxRTVwNEG0JO69VQ>? NFrPRXUzOzh2NECzPC=>
MES-SA NWH0[Y9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX22WG1OOTBizszN MU[3NkBp NVTTc|VzTE2VTx?= NXj1Z24{UUN3ME22Mlk5QSEQvF2= M3\rVVI{QDR2MEO4
22Rv1 NYW5TFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjZ[GEyOCEQvF2= NVjGXFREPzJiaB?= NGfzfIJFVVOR M4e0bmlEPTB;MUCg{txO NVzYWWE6OjN6NESwN|g>
647-V MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Q[no6OTBizszN NGjVRm04OiCq MXnEUXNQ MnLITWM2OD1zMDFOwG0> M2PsTlI{QDR2MEO4
786-O MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxNEDPxE1? NYXzRm11PzJiaB?= NFm1U4JFVVOR MVLJR|UxRTFyIN88US=> MkDxNlM5PDRyM{i=
A172 M122cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3TNVAh|ryP NEnjOFA4OiCq MVzEUXNQ NHqwU|JKSzVyPUGwJO69VQ>? MV:yN|g1PDB|OB?=
A204 NUXHcYFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYixNEDPxE1? M{TKOVczKGh? MXfEUXNQ MoDyTWM2OD1zMDFOwG0> NYfaWplkOjN6NESwN|g>
A427 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5PVMyOCEQvF2= NITkRmg4OiCq NYrkTWdHTE2VTx?= NY\tXG93UUN3ME2xNEDPxE1? NGDkTmUzOzh2NECzPC=>
A431 NVi1TWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmzTW9GOTBizszN NX;YNY81PzJiaB?= M13Xe2ROW09? NFHJOnVKSzVyPUGwJO69VQ>? NF2z[2MzOzh2NECzPC=>
A2780 NYPNcVlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\wXlExKM7:TR?= NWL1bnpRPzJiaB?= NETiRYJFVVOR NVnEbXdWUUN3ME2xNEDPxE1? MX[yN|g1PDB|OB?=
ARH-77 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNEDPxE1? M17jPVczKGh? NWW0NY1CTE2VTx?= MWnJR|UxRTFyIN88US=> MoXnNlM5PDRyM{i=
Be(2)C M1T6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn5SYQ5OTBizszN M13VNFczKGh? MWPEUXNQ NWnxfIpVUUN3ME2xNEDPxE1? NYLjZ2RzOjN6NESwN|g>
BT-20 M3Hpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq3dncyOCEQvF2= M3u1TFczKGh? M17qNGROW09? NU\TVHh{UUN3ME2xNEDPxE1? NHy0VGMzOzh2NECzPC=>
BxPc3 M1nsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq2NHhQOTBizszN MWe3NkBp NVHJfGQ{TE2VTx?= M1;2W2lEPTB;MUCg{txO M336bVI{QDR2MEO4
C-4 I MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TzSlExKM7:TR?= NUn0bGRPPzJiaB?= NEG1SHFFVVOR M3TzemlEPTB;MUCg{txO M4D6XVI{QDR2MEO4
C33A NXTaXIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYryV5JqOTBizszN Mm\JO|IhcA>? MnHOSG1UVw>? NH\oO2VKSzVyPUGwJO69VQ>? NHL0N4wzOzh2NECzPC=>
CAL-27 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxNEDPxE1? NHXRTIk4OiCq NFzjS3VFVVOR MlL6TWM2OD1zMDFOwG0> NVjJcZhrOjN6NESwN|g>
CAL-62 NV7ZWFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T1RVExKM7:TR?= M{C5SVczKGh? M{TLPGROW09? NVntc2E3UUN3ME2xNEDPxE1? M4fOXFI{QDR2MEO4
Calu-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHk[GkyOCEQvF2= M{\FUlczKGh? M1P6c2ROW09? MVHJR|UxRTFyIN88US=> MlLMNlM5PDRyM{i=
CaOV3 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNEDPxE1? MYq3NkBp MlixSG1UVw>? MonGTWM2OD1zMDFOwG0> M2LYdlI{QDR2MEO4
CGTHW1 NIjMc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nhV|ExKM7:TR?= MWG3NkBp M4q3RmROW09? NEnCdJZKSzVyPUGwJO69VQ>? NXTLc21IOjN6NESwN|g>
CHL-1 NVvTcWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi5UJBiOTBizszN MmDKO|IhcA>? MX3EUXNQ NIDEXXFKSzVyPUGwJO69VQ>? M2DWR|I{QDR2MEO4
Colo320DM NVfteXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXexNEDPxE1? NXeyfY57PzJiaB?= M1[wbmROW09? MnHzTWM2OD1zMDFOwG0> MofDNlM5PDRyM{i=
Colo704 NHLCfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNcHgyOCEQvF2= MVO3NkBp NEX0V|BFVVOR MYHJR|UxRTFyIN88US=> NF\uNWEzOzh2NECzPC=>
COR-L23 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofZNVAh|ryP NIW5cVU4OiCq MYnEUXNQ Mkf0TWM2OD1zMDFOwG0> MWWyN|g1PDB|OB?=
CRO-AP2 M{DrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXpRlUyOCEQvF2= MYW3NkBp M{jQXGROW09? NEnCSVRKSzVyPUGwJO69VQ>? MV[yN|g1PDB|OB?=
Daudi NWnseZJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WxWlExKM7:TR?= Ml7rO|IhcA>? NHr0TpNFVVOR M3mycWlEPTB;MUCg{txO M3XUeFI{QDR2MEO4
DOTC 24510 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfldodnOTBizszN MkH0O|IhcA>? NYrOVnUxTE2VTx?= MnzrTWM2OD1zMDFOwG0> M1L2fVI{QDR2MEO4
DU-145 M4TXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFftSW8yOCEQvF2= M{KwZVczKGh? MlXNSG1UVw>? M3nve2lEPTB;MUCg{txO Mlz6NlM5PDRyM{i=
EB-3 NEDBcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3OfW0yOCEQvF2= MmPqO|IhcA>? MlriSG1UVw>? Mlj5TWM2OD1zMDFOwG0> NXG4ZWhQOjN6NESwN|g>
EFM-19 M4OwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LLfFExKM7:TR?= Mn\UO|IhcA>? NEGxXWhFVVOR NGDpWIdKSzVyPUGwJO69VQ>? NXrUUGtlOjN6NESwN|g>
EKVX MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmxNEDPxE1? MWG3NkBp M1\pdGROW09? NYjCOHlKUUN3ME2xNEDPxE1? NYXEbXVvOjN6NESwN|g>
FaDu MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fGTVExKM7:TR?= MW[3NkBp M3jXSWROW09? NIHLbnBKSzVyPUGwJO69VQ>? NWTjeZlOOjN6NESwN|g>
G401 M1XmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnUb25uOTBizszN NUPXUWJIPzJiaB?= M1rXcWROW09? MkPITWM2OD1zMDFOwG0> Ml7BNlM5PDRyM{i=
HCC-70 NWO4VI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxNEDPxE1? M2DYRlczKGh? NXu3VYVOTE2VTx?= NYXIRmwzUUN3ME2xNEDPxE1? Mm\BNlM5PDRyM{i=
HCC-1954 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjyXFcyOCEQvF2= NVL6SXl[PzJiaB?= NVzOTZZxTE2VTx?= MWnJR|UxRTFyIN88US=> M3XHS|I{QDR2MEO4
Hela MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLnVW5VOTBizszN MYm3NkBp M4HKNWROW09? NGrqPWtKSzVyPUGwJO69VQ>? NVvLN3h7OjN6NESwN|g>
Hep3B MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfqUVYyOCEQvF2= M4XNSVczKGh? M3Xm[2ROW09? MkLKTWM2OD1zMDFOwG0> MVOyN|g1PDB|OB?=
HMCB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLaT|hVOTBizszN NH;vdlM4OiCq M3zieWROW09? NXfkNYl7UUN3ME2xNEDPxE1? M3XLWlI{QDR2MEO4
HN5 NEfkVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETse3AyOCEQvF2= NInyTHU4OiCq NUTXTFF{TE2VTx?= MV3JR|UxRTFyIN88US=> M4XuflI{QDR2MEO4
HOS NInZSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXSSnAyOCEQvF2= M{jiRlczKGh? MYXEUXNQ NX\GU2NXUUN3ME2xNEDPxE1? MUWyN|g1PDB|OB?=
HPAF-II NHfr[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDOOXluOTBizszN MYG3NkBp MX\EUXNQ NH3V[GlKSzVyPUGwJO69VQ>? NITsfIczOzh2NECzPC=>
Hs746.T Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DJdFExKM7:TR?= M3:0[|czKGh? NX\Yb3R4TE2VTx?= MnHHTWM2OD1zMDFOwG0> M1TVPFI{QDR2MEO4
HT MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTwbmVMOTBizszN NVzEZok2PzJiaB?= NWO5UVhyTE2VTx?= M1jue2lEPTB;MUCg{txO MUKyN|g1PDB|OB?=
HT-3 M4fNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLNe5kyOCEQvF2= NVLjfZJCPzJiaB?= M1X0fmROW09? MlTCTWM2OD1zMDFOwG0> NF;XTngzOzh2NECzPC=>
HuNS-1 NXXlVZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDWNVAh|ryP MY[3NkBp NUPHbXZPTE2VTx?= MVLJR|UxRTFyIN88US=> NFPNVHkzOzh2NECzPC=>
IGROV1 NV:2dWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS2VnBNOTBizszN NF7qe3E4OiCq NFvmTVFFVVOR MmLTTWM2OD1zMDFOwG0> NVzvRW9UOjN6NESwN|g>
J82 M2PafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[xOVExKM7:TR?= NYnaU3dFPzJiaB?= MmDkSG1UVw>? MnH0TWM2OD1zMDFOwG0> NIK3Z|gzOzh2NECzPC=>
JM1 NGjVTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HtOFExKM7:TR?= MYi3NkBp NYnnfW1vTE2VTx?= NV;tRYFNUUN3ME2xNEDPxE1? MnjiNlM5PDRyM{i=
Kato III NHX5SVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? MUW3NkBp MUHEUXNQ MXrJR|UxRTFyIN88US=> MYeyN|g1PDB|OB?=
KHOS-240S MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNEDPxE1? M4\kWlczKGh? MkDVSG1UVw>? M3n0N2lEPTB;MUCg{txO MkPZNlM5PDRyM{i=
KM-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjkO5MyOCEQvF2= M{jZSVczKGh? NYTXepBFTE2VTx?= Mm[yTWM2OD1zMDFOwG0> MmLkNlM5PDRyM{i=
KPL-1 NYHhTYxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxNEDPxE1? M{PZVFczKGh? MXzEUXNQ NUDIbGNEUUN3ME2xNEDPxE1? M13jOlI{QDR2MEO4
KYSE-30 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXRNVAh|ryP MX[3NkBp MVLEUXNQ MWXJR|UxRTFyIN88US=> M1H4ZlI{QDR2MEO4
LNCaP M4\wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OweFExKM7:TR?= NYD6fXdPPzJiaB?= MVrEUXNQ NIPHU41KSzVyPUGwJO69VQ>? NFGzToIzOzh2NECzPC=>
MCF-7 NEO2XYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYeIoyOCEQvF2= NUT5[oo{PzJiaB?= NYPkfVdxTE2VTx?= MUHJR|UxRTFyIN88US=> M{ftRlI{QDR2MEO4
MC-IXC M1Kwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqyNVAh|ryP MWG3NkBp NHnxUZFFVVOR NWjpPHE5UUN3ME2xNEDPxE1? M2fVeFI{QDR2MEO4
MDA-MB-175 VII NITkfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;2bmhqOTBizszN M{PjV|czKGh? MmLhSG1UVw>? NVf3e2o5UUN3ME2xNEDPxE1? MlPlNlM5PDRyM{i=
MDA-MB-468 NUTHOlh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m5bFExKM7:TR?= NG\IbJg4OiCq Ml;ISG1UVw>? M3O3XWlEPTB;MUCg{txO NXrISWJtOjN6NESwN|g>
MiaPaCa NFG2d|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvtcmsyOCEQvF2= MkW1O|IhcA>? MW\EUXNQ M3vZNmlEPTB;MUCg{txO NX\LZZUyOjN6NESwN|g>
Molt-4 NV\wbpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFflS2wyOCEQvF2= NWrXRnpzPzJiaB?= MY\EUXNQ NVrNO2JGUUN3ME2xNEDPxE1? Mm\jNlM5PDRyM{i=
NCI-ADR/RES NXHS[WV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfzSmhTOTBizszN NYX3ZnhMPzJiaB?= NIjabm1FVVOR MW\JR|UxRTFyIN88US=> MoTsNlM5PDRyM{i=
NCI-H69 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nhd|ExKM7:TR?= MUK3NkBp MlzESG1UVw>? NE\0cW9KSzVyPUGwJO69VQ>? NXHNRnJmOjN6NESwN|g>
NCI-H82 NU[yfIRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULMSpFpOTBizszN NXLScng1PzJiaB?= NXXie3AyTE2VTx?= MXHJR|UxRTFyIN88US=> NXPVOJc5OjN6NESwN|g>
NCI-N87 NF\HelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[xNEDPxE1? MnflO|IhcA>? MUfEUXNQ Ml;UTWM2OD1zMDFOwG0> NEfHflYzOzh2NECzPC=>
NCI-H146 NYjjZ2gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxNEDPxE1? MnvBO|IhcA>? M2e4XmROW09? MVrJR|UxRTFyIN88US=> M2DabVI{QDR2MEO4
NCI-H157 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ZSVRmOTBizszN MYi3NkBp NHzkNlJFVVOR NEXzfopKSzVyPUGwJO69VQ>? M{LhUFI{QDR2MEO4
NCI-H187 NUfCNppQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNEDPxE1? NH7Zeo84OiCq MYXEUXNQ MoHUTWM2OD1zMDFOwG0> MlH0NlM5PDRyM{i=
NCI-H209 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PhSlExKM7:TR?= MmTRO|IhcA>? MXTEUXNQ NXHH[GxGUUN3ME2xNEDPxE1? M4PVdFI{QDR2MEO4
NCI-H226 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnEfpNtOTBizszN NYrn[W9wPzJiaB?= Mn3ISG1UVw>? MlnXTWM2OD1zMDFOwG0> NEThTHUzOzh2NECzPC=>
NCI-H292 NWPCe4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnrNVAh|ryP NHrUNnA4OiCq M4roZWROW09? NInHZ|ZKSzVyPUGwJO69VQ>? M3HENVI{QDR2MEO4
NCI-H322 NGTmOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGxNEDPxE1? NGDaSng4OiCq M{DI[WROW09? NHrNfXZKSzVyPUGwJO69VQ>? NHXibo0zOzh2NECzPC=>
NCI-H358 M132Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TZelExKM7:TR?= MorKO|IhcA>? NEDr[5FFVVOR M2XyZmlEPTB;MUCg{txO NEfiPYQzOzh2NECzPC=>
NCI-H520 NHHocoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\KfVQyOCEQvF2= NWTpdZhoPzJiaB?= MmPqSG1UVw>? M3zQNmlEPTB;MUCg{txO NEfrNlkzOzh2NECzPC=>
NCI-H526 M4OyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLkNVAh|ryP NWDVUYVGPzJiaB?= MVLEUXNQ Mn;aTWM2OD1zMDFOwG0> NYXnWWZOOjN6NESwN|g>
NCI-H630 NWLmZ4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVWVExKM7:TR?= M{Hlb|czKGh? M3rjfWROW09? M4W1TWlEPTB;MUCg{txO NFzG[3gzOzh2NECzPC=>
NCI-H661 NF7mWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HJbFExKM7:TR?= NXThSVhMPzJiaB?= MmHlSG1UVw>? MofPTWM2OD1zMDFOwG0> NETCeIwzOzh2NECzPC=>
NCI-H716 M37rOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHQfWIyOCEQvF2= Mk\mO|IhcA>? M2nZdWROW09? M2LrcGlEPTB;MUCg{txO MoDMNlM5PDRyM{i=
NCI-H1563 NV7ielAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xNEDPxE1? NEixcIQ4OiCq MmnYSG1UVw>? MVvJR|UxRTFyIN88US=> NWj3co45OjN6NESwN|g>
NCI-H1792 NETCOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfIZ2JSOTBizszN M2HkdFczKGh? MoPNSG1UVw>? NWnHRmJ[UUN3ME2xNEDPxE1? M3O5[FI{QDR2MEO4
NCI-H2030 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDHRpMyOCEQvF2= NIfkSHM4OiCq NGXWNXhFVVOR MmXITWM2OD1zMDFOwG0> NGrVZ|gzOzh2NECzPC=>
NCI-H2052 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTtSG4{OTBizszN M2nMOVczKGh? NWrIcW5ZTE2VTx?= NWPUZY5bUUN3ME2xNEDPxE1? MVOyN|g1PDB|OB?=
NCI-H2122 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrLRZgyOCEQvF2= NITmXXo4OiCq M2fnSmROW09? MYDJR|UxRTFyIN88US=> MXeyN|g1PDB|OB?=
NCI-H2228 M133[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC4NVAh|ryP NV7yc5hiPzJiaB?= MWXEUXNQ NV;QW4xuUUN3ME2xNEDPxE1? M4nI[VI{QDR2MEO4
OE-19 NXXSc2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xNEDPxE1? NXPacZptPzJiaB?= M{HEc2ROW09? Mki0TWM2OD1zMDFOwG0> MofMNlM5PDRyM{i=
OE-21 NXTZVFltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL3NVAh|ryP NX;GbmFsPzJiaB?= MWLEUXNQ NVzDV3Y4UUN3ME2xNEDPxE1? NYf5S2JNOjN6NESwN|g>
OE-33 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNEDPxE1? NHn0bIc4OiCq NVvTZoNzTE2VTx?= NUTYdWVXUUN3ME2xNEDPxE1? Ml74NlM5PDRyM{i=
OVCAR-3 NVXjOoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzpfpJxOTBizszN MknFO|IhcA>? M3HyOWROW09? M1zPV2lEPTB;MUCg{txO NET2bVQzOzh2NECzPC=>
OVCAR-4 NVmzT3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPFNVAh|ryP Mk[1O|IhcA>? MYrEUXNQ MUPJR|UxRTFyIN88US=> MnPnNlM5PDRyM{i=
OVCAR-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LB[FExKM7:TR?= M{fBS|czKGh? NILzc|BFVVOR NIr6emtKSzVyPUGwJO69VQ>? MVKyN|g1PDB|OB?=
P3HR-1 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG3VVk6OTBizszN NHTFXFg4OiCq NFi3NGFFVVOR NWHnbJJuUUN3ME2xNEDPxE1? NVPMcI1nOjN6NESwN|g>
PC-3 NXPmT|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuxNEDPxE1? MYC3NkBp NVG2foVXTE2VTx?= NFrDbIlKSzVyPUGwJO69VQ>? M4LkUVI{QDR2MEO4
Raji MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHCNVAh|ryP NYXnV2JOPzJiaB?= NH\iOGJFVVOR M17TV2lEPTB;MUCg{txO MlnzNlM5PDRyM{i=
RD MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? NYfCZ2JEPzJiaB?= NX7Le|N[TE2VTx?= NUfpUGZWUUN3ME2xNEDPxE1? NX;kPJNKOjN6NESwN|g>
RD-ES NU\XcYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXHWlcyOCEQvF2= M1TQbVczKGh? MlzrSG1UVw>? MXTJR|UxRTFyIN88US=> NU\YWW82OjN6NESwN|g>
RL M2qzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOxTXQyOCEQvF2= NWnITXBDPzJiaB?= NIrPU49FVVOR M3jz[2lEPTB;MUCg{txO NV3S[ppCOjN6NESwN|g>
SaOS2 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu4fnEyOCEQvF2= NWS4PJNNPzJiaB?= Ml7MSG1UVw>? M4\0S2lEPTB;MUCg{txO MXmyN|g1PDB|OB?=
SCC-9 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnWWYgyOCEQvF2= MUe3NkBp MUfEUXNQ NIDhNlZKSzVyPUGwJO69VQ>? NEC2fZEzOzh2NECzPC=>
SCC-12 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjteIhZOTBizszN MX23NkBp NX;u[ZBXTE2VTx?= MYPJR|UxRTFyIN88US=> MnzNNlM5PDRyM{i=
SCC-13 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\sWVlCOTBizszN MU[3NkBp MUXEUXNQ NWnpNpc5UUN3ME2xNEDPxE1? NEPLTlMzOzh2NECzPC=>
SCC-15 NFviSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfNNVAh|ryP MonTO|IhcA>? MonnSG1UVw>? MonaTWM2OD1zMDFOwG0> NFPvdIIzOzh2NECzPC=>
SCC-25 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXKRWJYOTBizszN MVi3NkBp NGjYc3RFVVOR NH;ifJhKSzVyPUGwJO69VQ>? M{THelI{QDR2MEO4
SCLC-3 M2fKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHBU|IyOCEQvF2= M3:yWlczKGh? NIm0S3BFVVOR M4L2OWlEPTB;MUCg{txO MXiyN|g1PDB|OB?=
SF-268 NInYVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPaNVAh|ryP MVm3NkBp NULwSYhNTE2VTx?= Mk\UTWM2OD1zMDFOwG0> MmfNNlM5PDRyM{i=
SF-295 M1LJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTkV|UyOCEQvF2= NI\ieVg4OiCq Ml\ESG1UVw>? NE\kOYRKSzVyPUGwJO69VQ>? NX[3fmpXOjN6NESwN|g>
SJRH30 NWThUoc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPuNVAh|ryP NGj0[XA4OiCq M2X1TmROW09? NWjNT2FRUUN3ME2xNEDPxE1? M{fvV|I{QDR2MEO4
SK-BR-3 NHm5fXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnDTpgxOTBizszN MnjmO|IhcA>? MV;EUXNQ NYmzT2Q1UUN3ME2xNEDPxE1? MWiyN|g1PDB|OB?=
SK-LMS-1 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWxNEDPxE1? NGTHNJg4OiCq NFGwWo9FVVOR MWDJR|UxRTFyIN88US=> NV25S3lVOjN6NESwN|g>
SK-N-DZ MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojuNVAh|ryP NV;jelg4PzJiaB?= MWfEUXNQ NH\4cXRKSzVyPUGwJO69VQ>? M324Z|I{QDR2MEO4
SK-N-F1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? M1nkU|czKGh? NYfjdHR{TE2VTx?= MorkTWM2OD1zMDFOwG0> M1zs[VI{QDR2MEO4
SKOV-3 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF21UYUyOCEQvF2= MonDO|IhcA>? NGfCNHpFVVOR MULJR|UxRTFyIN88US=> NUPvdXBJOjN6NESwN|g>
SK-UT-1 NYHUW4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNdHloOTBizszN NWr4Z3lJPzJiaB?= NVrI[5J5TE2VTx?= M1XQTGlEPTB;MUCg{txO NWXKUpJDOjN6NESwN|g>
SN12C NX3zWVYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrINVAh|ryP M{PpRlczKGh? MlSySG1UVw>? MXfJR|UxRTFyIN88US=> MnfDNlM5PDRyM{i=
SNB-19 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fq[|ExKM7:TR?= MlnCO|IhcA>? MmXqSG1UVw>? NIDHZlBKSzVyPUGwJO69VQ>? MUCyN|g1PDB|OB?=
SNU-5 NUTuSod[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTnNW1qOTBizszN MkjmO|IhcA>? MnXvSG1UVw>? NFjqcoZKSzVyPUGwJO69VQ>? MojFNlM5PDRyM{i=
SNU-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GzOFExKM7:TR?= NXKxfXZyPzJiaB?= MWrEUXNQ M2LRbGlEPTB;MUCg{txO M17MbVI{QDR2MEO4
SNU-398 NXHJfHJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDNdmVlOTBizszN MUW3NkBp NV7BN5FWTE2VTx?= NIXpZ2ZKSzVyPUGwJO69VQ>? NXj2SFZ4OjN6NESwN|g>
SNU-449 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfKXI8yOCEQvF2= MkDDO|IhcA>? NXOwZWY1TE2VTx?= NVjH[lFWUUN3ME2xNEDPxE1? NWHDb|htOjN6NESwN|g>
SR MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv4dm9TOTBizszN MYi3NkBp MVrEUXNQ MW\JR|UxRTFyIN88US=> NXO3N3RGOjN6NESwN|g>
ST486 NHj6R3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPDNVAh|ryP M3zoNFczKGh? NWrGe3huTE2VTx?= NFixVGdKSzVyPUGwJO69VQ>? M3nEbVI{QDR2MEO4
SW579 NIXNXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xNEDPxE1? NGLZcno4OiCq NE\K[IhFVVOR NEnqcINKSzVyPUGwJO69VQ>? NXW4[4pROjN6NESwN|g>
SW684 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;z[lExKM7:TR?= NEDjPXM4OiCq M4ryZmROW09? NVz5O|I5UUN3ME2xNEDPxE1? NYq4NGNOOjN6NESwN|g>
SW-780 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTTNVAh|ryP NYHXOox4PzJiaB?= Mm\USG1UVw>? MV3JR|UxRTFyIN88US=> NFHPR3QzOzh2NECzPC=>
SW900 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\WO3g5OTBizszN M1HFRVczKGh? NX;tRXVXTE2VTx?= M1\DO2lEPTB;MUCg{txO M{LMWVI{QDR2MEO4
SW1088 NGDPdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[wSFExKM7:TR?= M33NPFczKGh? M1vXdGROW09? NV\w[HlnUUN3ME2xNEDPxE1? Ml\oNlM5PDRyM{i=
SW1463 NW\iO3hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjqZ3ZSOTBizszN M3zodVczKGh? MXXEUXNQ M3PKWmlEPTB;MUCg{txO NFfOUHEzOzh2NECzPC=>
SW1990 NFnufVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[xZoMyOCEQvF2= NIDvcHQ4OiCq NHjOcVFFVVOR NUPHTXM2UUN3ME2xNEDPxE1? M4WzS|I{QDR2MEO4
T47D MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixNEDPxE1? MX63NkBp NELFUHdFVVOR MVXJR|UxRTFyIN88US=> MWWyN|g1PDB|OB?=
TE381.T MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnxZYlsOTBizszN NXPjR255PzJiaB?= M{DV[WROW09? NXL4To1SUUN3ME2xNEDPxE1? M4i0UlI{QDR2MEO4
TK-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nN[lExKM7:TR?= MVu3NkBp MWLEUXNQ MlrsTWM2OD1zMDFOwG0> NVTBc3JLOjN6NESwN|g>
U2OS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq3TZhmOTBizszN MX23NkBp M37FSGROW09? MlvpTWM2OD1zMDFOwG0> MnfxNlM5PDRyM{i=
U251 NXjLR5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfRNVAh|ryP NWTLdnZqPzJiaB?= NEPnSYFFVVOR M3fhbGlEPTB;MUCg{txO NFrUbWIzOzh2NECzPC=>
UACC-812 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHSNVAh|ryP MUW3NkBp MmrKSG1UVw>? NF;scIpKSzVyPUGwJO69VQ>? NIfIcG8zOzh2NECzPC=>
YAPC MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zOGNjOTBizszN M4\3d|czKGh? M{LaV2ROW09? MUHJR|UxRTFyIN88US=> NUPNSpJvOjN6NESwN|g>
ZR-75-1 NXjJWpE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXexNEDPxE1? MWK3NkBp NX7LPGVzTE2VTx?= MV3JR|UxRTFyIN88US=> MknUNlM5PDRyM{i=
A375 M4W1e2Z2dmO2aX;uJIF{e2G7 MmTrNU4zKM7:TR?= NELBS5o1KGh? Mo\lSG1UVw>? MXTJcohq[mm2aX;uJI9nKHCqb4PwbI9zgWyjdHnvckBw\iCPRVusJGVTUyxiYX7kJHM3WA>? M3exPFIzOzh7NEex
YUSIT1 NUHaPJF1TnWwY4Tpc44h[XO|YYm= M1\xZWROW09? MXzy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0> M4PrOlIzOzh7NEex
MeWo NXOxRZFyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUe4OHN4TE2VTx?= NVjVSVFZUUN3MDC9JFk5PyCwTR?= MnniNlYxOTh3MkS=
WiDr NWnnV2JVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWDEUXNQ M3XNOGlEPTBiPTC3OkBvVQ>? NGHtc3ozPjBzOEWyOC=>
Colo-205 M1m3dGZ2dmO2aX;uJIF{e2G7 NHjDPHkyKM7:TR?= MoHnOEBl NFq4ZWFFVVOR MnrpTY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm MnHTNlU{QDFzNUK=
RBW-1 Mn21SpVv[3Srb36gZZN{[Xl? M1HLblEh|ryP MoTnSG1UVw>? MWfOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NHHmNmgzPDh6NU[5NC=>
RBO-1 NWTDNIMzTnWwY4Tpc44h[XO|YYm= NF3JZXgyKM7:TR?= NELz[ldFVVOR MV;Jcohq[mm2aX;uJI9nKE2nazCxM|IheGixc4Doc5J6dGG2aX;u MoHoNlQ5QDV4OUC=
RBO-2 MnXpSpVv[3Srb36gZZN{[Xl? NXPneXBCOSEQvF2= Mnj4SG1UVw>? M1:xO2lvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v M3Pvd|I1QDh3Nkmw
RBOW NVq0VnRbTnWwY4Tpc44h[XO|YYm= MmTnNUDPxE1? NFzSR4pFVVOR NFTQXFZKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NFWz[G8zPDh6NU[5NC=>
M257 M3XlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\uNVAxKG6P NUD5Wm5NPzJiaB?= MmLvSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI NH[wTpkzOzNzN{S0Oi=>
LCP NYq4TnVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrXcm0yODBibl2= MYW3NkBp NGnFfZdKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v M{XLSlI{OzF5NES2
WM266 M{\rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHpTosyODBibl2= M3rnfVczKGh? Ml;FTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKFePMk[2JINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEHEJI12fGGwdHH0bY9v MlfhNlM{OTd2NE[=
M257 NU\6UGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNFAhdk1? NEXy[FE4OiCq MVXEc4V{KG6xdDDpcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ? NU\LbJhJOjN|MUe0OFY>
LCP MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fie|ExOCCwTR?= NUXIdm5jPzJiaB?= NHnjcZJKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUGNRKGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBTKG23dHHueIF1cW:w MUKyN|MyPzR2Nh?=
WM266 M1XRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\FNW4yODBibl2= NHK0RWo4OiCq MmPLTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w NUfCTnpwOjN|MUe0OFY>

... Click to View More Cell Line Experimental Data
体内研究 Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
30% PEG400+0.5% Tween80+5% propylene glycol 		8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 519.56
化学式

C23H20F3N5O2S2
CAS号 1195765-45-7
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01153763 Completed Melanoma GlaxoSmithKline August 9 2010 Phase 2
NCT02858921 Recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis November 8 2017 Phase 2
NCT01978236 Terminated Melanoma and Brain Metastases GlaxoSmithKline April 8 2014 Phase 2
NCT01682083 Active not recruiting Melanoma Novartis Pharmaceuticals|Novartis January 8 2013 Phase 3
NCT01340833 Completed Cancer GlaxoSmithKline June 8 2011 Phase 1
NCT01723202 Active not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

  • 泛Raf抑制剂

    AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.

  • FDA批准的Raf抑制剂

    Sorafenib Tosylate : Approved by FDA for advanced renal cancer。

  • 最新的Raf抑制剂

    TAK-632 New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

相关Raf产品

  • LY3009120 New

    LY03009120是一种有效的泛Raf抑制剂，在A375细胞中对A-raf，B-Raf，和 C-Raf的IC50分别为44 nM，31-47 nM，和 42 nM。Phase 1。

  • GDC-0994 New

    GDC-0994 是一种有效的，可口服的， 具有选择性的 ERK1/2 抑制剂, 其IC50分别为1.1 nM和0.3 nM。 Phase 1。

  • Ulixertinib (BVD-523, VRT752271) New

    Ulixertinib (BVD-523, VRT752271)是有效的可逆ERK1/ERK2抑制剂，其抑制ERK2的IC50<0.3 nM 。Phase 1。

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204)是一种新型有效的B-RafV600E抑制剂，IC50为31 nM。Vemurafenib对B-RafV600E的选择性比对野生型B-Raf的选择性高10倍，在细胞实验中，选择性可高100倍以上。

    Features:PLX4032是新型有效的B-RAFV600E 肿瘤蛋白抑制剂。

  • Sorafenib

    Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂，无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

  • Sorafenib Tosylate

    Sorafenib Tosylate是一种酪氨酸激酶(VEGFR和PDGFR)和RAF/MEK/ERK级联抑制剂，同时作用于Raf-1，wtBRAF和V599EBRAF，IC50分别为6 nM， 22 nM和38 nM。

  • PLX-4720

    PLX-4720是一种有效的，选择性的B-RafV600E抑制剂，无细胞试验中IC50为13 nM，同样有效地作用于c-Raf-1(Y340D和Y341D突变型)，作用于B-RafV600E比作用于野生型B-Raf选择性高10倍。

  • TAK-632

    TAK-632是强效的泛Raf抑制剂，无细胞试验中对B-Raf(wt)和C-Raf的IC50分别为8.3 nM and 1.4 nM， 对其他被测试的酶抑制效果较差或者没有效果。

  • GDC-0879

    GDC-0879是一种新型有效的，选择性B-Raf抑制剂，在A375和Colo205细胞中IC50为0.13 nM，对c-Raf也有抑制作用；对其他蛋白激酶没有抑制作用。

  • GW5074

    GW5074是一种有效的，选择性的c-Raf抑制剂，IC50为9 nM，对JNK1/2/3， MEK1， MKK6/7， CDK1/2， c-Src， p38 MAP， VEGFR2和c-Fms没有抑制活性。

Tags: 购买Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)供应商 | 采购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)价格 | Dabrafenib (GSK2118436)生产 | 订购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID